Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12298852 | 1.00 | PTGER4 (0.52) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL1865254 | 0.93 | PTGER4 (0.52) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL10750938 | 0.88 | PTGER4 (0.57) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL27904162 | 0.87 | PTGER4 (0.47) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL12298855 | 0.84 | MEN1 (0.48) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL635958 | 0.83 | PTGER4 (0.40) | PTGER4PTGER3PTGER2KMT2A | |
| SCHEMBL13572913 | 0.81 | PTGER4 (0.41) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL12298851 | 0.81 | MEN1 (0.44) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL16509685 | 0.80 | CHRM2 (0.43) | PTGER4PTGER3PTGER2KMT2A | |
| SCHEMBL1866699 | 0.80 | PTGER4 (0.44) | PTGER4PTGER3PTGER2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858650-B2 | Medicinal composition for inhalation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7683094-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-7402605-B2 | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20080114043-A1 | Medicinal Composition for Inhalation | ONO PHARMACEUTICAL CO., LTD (JP) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114043-A1 | Medicinal Composition for Inhalation | PTGER2, PTGER1, PTGIS | PTGER4 10/4885PTGER3 6/4885PTGER2 1/4885 |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | PTGER4 19/4885PTGER3 16/4885PTGER2 1/4885 |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | PTGER4 19/4885PTGER3 16/4885PTGER2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.